Delivery Order SPE2DR25D1004-SPE2DR26FSVA0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $24,804.64 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on November 17, 2025. This competitive, firm fixed-price delivery order is structured with an ultimate completion date of November 18, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania facility. The contract carries no set-aside designation, indicating it was awarded through open competition. This delivery...
- The Defense Logistics Agency awarded a $20,513.52 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, firm fixed-price delivery order is expected to be completed by September 9, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting the vendor's capability to compete in open federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $6,433.92. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is set for completion by November 10, 2025, with performance occurring at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $12,544.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award under the company's broader pharmaceutical supply relationships with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $8,579.95. This non-competitive, firm fixed-price delivery order is scheduled for completion by November 14, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a continuation of the pharmaceutical supply chain supporting federal medical procurement needs. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors, with a contract ceiling value of $3,603.02 and an ultimate completion date of October 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- SPE2DR25D1004Indefinite Delivery Contract
- SPE2DR25D1004-SPE2DR26FSVA0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $19,074.20. This contract represents a firm fixed price delivery order with an ultimate completion date of November 18, 2025, and carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company maintains an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Dupixent (dupilumab) is a biologic treatment used for allergic and inflammatory conditions, and its inclusion in this delivery order reflects the company's role in supplying specialized pharmaceuticals to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.1k | 11/17/25 |